Status:

UNKNOWN

Customized Choice of Oral P2Y12 Receptor Blocker

Lead Sponsor:

Italian Society of Invasive Cardiology

Collaborating Sponsors:

Eustrategy

Conditions:

Acute Coronary Syndrome

Coronary Angioplasty

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

A subset of patients recruited in the main MATRIX study will be randomized after intervention but before discharge to standard of care (the treating physician will decide which oral P2Y12 inhibitor wi...

Detailed Description

Up to 20-30% of clopidogrel treated patients do not adequately respond to the drug and are at higher risk for ischemic events including death, myocardial infarction, stroke and stent thrombosis. Resi...

Eligibility Criteria

Inclusion

  • patients recruited in the main MATRIX study who underwent coronary angioplasty with stent placement.

Exclusion

  • unwillingness to sign this sub study specific informed consent

Key Trial Info

Start Date :

January 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2015

Estimated Enrollment :

4000 Patients enrolled

Trial Details

Trial ID

NCT01477775

Start Date

January 1 2012

End Date

December 1 2015

Last Update

September 3 2014

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

Azienda Ospedaliera Pugliese Ciaccio

Catanzaro, Calabria, Italy, 88100

2

University Hospital of Ferrara

Ferrara, Ferrara, Italy, 44100

3

Azienda Ospedaliera Fatebenefratelli e Oftalmico

Milan, MI, Italy, 20121

4

Spedali Civili di Brescia

Brescia, Italy